Pharmaceuticals

Hoth Therapeutics

Hoth Therapeutics released FY2026 Q1 earnings on May 15 (EST) with actual revenue of USD 0 and EPS of USD -0.1704

Hoth Therapeutics released FY2025 Q4 earnings on March 27 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1719 (forecast USD -0.1)

Hoth Therapeutics released FY2025 Annual Earnings on March 27 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.9031 (forecast USD -0.84)

Hoth Therapeutics, Inc. Obtains Chinese Patent for HT-KIT Technology

Hoth Therapeutics released FY2025 9 Months Earnings on November 12 (EST), with actual revenue of USD 0 and EPS of USD -0.7377

Hoth Therapeutics released FY2025 Q3 earnings on November 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.2977 (forecast USD -0.07)

Hoth Therapeutics, Inc.'s drug HT-KIT obtains FDA Orphan Drug Designation

Hoth Therapeutics to Release Operations and Progress in Drug Development

Hoth Therapeutics released FY2025 Q2 earnings on August 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.1699 (forecast USD -0.14)

Hoth Therapeutics released FY2025 Semi-Annual earnings on August 12 (EST), actual revenue USD 0, actual EPS USD -0.4379

Hoth Therapeutics Hosts Virtual KOL Event for EGFR Inhibitor Therapy Discussion

Hoth Therapeutics Inc. Announces Positive Preclinical Safety Data for HT-KIT

Hoth Therapeutics Obtains Japanese National Patent for Extended Monopoly

Hoth Therapeutics Submits Expanded Access Program Application for HT-001

Hoth Therapeutics Makes Progress in Clinical Innovations for Cancer Support Treatment

Hoth Therapeutics Hosts HT-001 Key Opinion Leader Event

Hoth Therapeutics Inc. Receives Notice from NASDAQ on Minimum Bid Price Requirement

Hoth Therapeutics released FY2025 Q1 earnings on May 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.273 (forecast USD -0.18)

Hoth Reports Q1 Loss of $3.48 Million

Hoth Therapeutics Inc Expected to Report Quarterly Loss of 26 Cents Per Share

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

HOTH

LABU

Hoth Therapeutics Inc. plans to rebrand as Rocket One Inc. to focus on AI semiconductor technologies and ultra-low-power AI computing. The board unanimously approved this strategic shift, which includes securing exclusive rights to technologies from Virginia Commonwealth University. The company will maintain its biotechnology operations while addressing AI infrastructure challenges. Hoth's shares fell 9.69% to $0.55 in premarket trading, reflecting a 20.9% decline over the past month.

benzinga_article

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

S&P 500

EXCLUSIVE: Hoth Therapeutics To Rebrand To Pursue AI Chip Technologies

Hoth Therapeutics is restructuring and rebranding as Rocket One, Inc. to enter the AI semiconductor market. The company has acquired exclusive rights to next-generation AI semiconductor technologies, focusing on energy efficiency for AI data centers. The restructuring aims to address power consumption challenges in AI infrastructure while continuing its biotechnology programs under a separate subsidiary. The move is supported by the Board of Directors and aims to capitalize on emerging opportunities in AI and advanced computing technologies.

StockTitan

AI Chip Energy Efficiency: Hoth Therapeutics Restructures as Rocket One Inc. to Enter the AI Semiconductor Infrastructure Market with Acquisition of Exclusive Rights to Next Generation AI Semiconductor Acceleration Technology Built on Non-Volatile Nanomagnetic Semiconductor Architecture | HOTH Stock News

IBBQ

SBIO

ARKG

Hoth Therapeutics, Inc. has received regulatory authorization in Spain for its Phase 2a CLEER Trial of HT-001, aimed at treating dermatologic toxicities associated with EGFR inhibitors in cancer patients. Interim results show significant efficacy, with over 65% of patients reporting reduced pain and itching, and no treatment disruptions. The trial's success supports Hoth's strategy for expanding its clinical research in Europe, highlighting HT-001's potential as a supportive care therapy in oncology.

prnewswire

Invesco Biotechnology & Genome ETF

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

16:17 ETHoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients

TVTX

AVNS

RYLPF

REPL

This week's biotech news highlights significant regulatory approvals and rejections, including FDA clearance for Royal Philips' AI-powered Spectral CT and full approval for Travere's FILSPARI for FSGS. Nxera Pharma's QUVIVIQ received Taiwan approval for insomnia, while Replimune faced a second FDA rejection for RP1 in melanoma. Notable acquisitions include Stereotaxis acquiring Robocath and American Industrial Partners' $1.27 billion deal for Avanos Medical. The landscape also features collaborations, such as Sana's partnership with Mayo Clinic for SC451.

rttnews

Travere Therapeutics

Avanos Medical

Koninklijke Philips N.V.

Replimune

Koninklijke Philips Elect

Sosei Group Corporation

Regeneron Pharma

Sanofi

Stereotaxis

Mesoblast

Mesoblast Limited

Weekly Buzz: FDA Okays TVTX, PHG; Rejects REPL; AIP Snaps Up AVNS; PDS, HOTH, SYRE, Paces Trials

Hoth Therapeutics, Inc. has resumed its At-the-Market Equity Offering Program after previously suspending it. The company filed a new prospectus supplement to its Form S-3 registration statement, allowing it to raise capital through securities sales. This move aims to enhance financial flexibility for ongoing operations and development programs, potentially impacting its funding strategy and existing shareholders. Hoth Therapeutics focuses on developing therapeutic solutions and utilizes equity programs for financing.

Tip Ranks

Hoth Therapeutics Resumes At-the-Market Equity Offering Program

Hoth Therapeutics(HOTH.US)

EXCLUSIVE: Hoth Therapeutics To Rebrand To Pursue AI Chip Technologies

16:17 ETHoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients

Weekly Buzz: FDA Okays TVTX, PHG; Rejects REPL; AIP Snaps Up AVNS; PDS, HOTH, SYRE, Paces Trials

Hoth Therapeutics Resumes At-the-Market Equity Offering Program